This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia and high cardiovascular risk. At 24 weeks follow-up LDL cholesterol reduction with alirocumab was 61% versus 0.8% placebo (p <0.0001). This reduction was maintained at 52 weeks. Jennifer Robinson2014-08-31 Original title: Long-term safety, tolerability and efficacy of alirocumab…
LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients
The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke, particularly in diabetic patients. Many statins may interfere with glycemic profile of patients and there is no information between different drugs for some specific populations. 1049 patients randomized to rosuvastatin (n = 524) versus atorvastatin (n = 504)…
PARADIGM-HF: New family of drugs for chronic heart failure
Therapy in heart failure has been to focus the neurohormonal pathways such as the renin-angiotensin-aldosterone system. Natriuretic peptides are metabolized by neprilysin enzyme. The LCZ696 is a new class of drug that inhibits the enzyme neprilysin. A total of 8436 patients with chronic heart failure functional class II-IV were included, elevated levels of NT-ProBNP and/or…
CONFIRM HF: Is it safe to replace intravenous iron in patients with chronic heart failure
This study aimed to assess whether iron replacement versus placebo could improve physical activity in patients with chronic heart failure and iron deficiency. 150 patients for the Iron group and 151 patients to placebo were randomized, physical ability was assessed with the 6 minutes walking test. In the group receiving iron improvement in the 11-meter…
NECTAR HF: Chronic vagal stimulation for heart failure with low ejection fraction
The increased sympathetic activity and reduced parasympathetic tone are important pathophysiological contributors to the progression of heart failure and are associated with a worse prognosis. The aim of this study was to determine if vagus nerve stimulation is a promising strategy to modulate autonomic function, cardiac remodeling, and progression of heart failure. The NECTAR HF…
POPE-2: Colchicine to prevent pericardial effusion after cardiac surgery
The incidence of asymptomatic pericardial effusion after cardiac surgery is high. The aim of this study was to evaluate whether colchicine would be able to reduce the volume of postoperative pericardial effusion. This multicenter, double-blind, placebo-controlled study, randomized 197 patients with high risk of cardiac tamponade determined by the presence of persistent pericardial effusion from…
MORE-CRT: Cardiac resynchronization with quadrupole electrode reduces complications
In approximately 10% of patients for resynchronization therapy implantation of ventricular lead is not possible for anatomical difficulties, by phrenic hyper-stimulation or low stimulous capture. This study was designed with the assumption that the quadrupole electrodes will result in fewer interventions both during implantation and during follow-up than bipolar electrodes. The work included 1068 patients…
COPPS-2: Colchicine for prevention of post-pericardiotomy syndrome and postoperative atrial fibrillation
180 patients with colchicine 0.5 mg twice daily from 48-72 hs. before surgery versus 180 patients to placebo were randomized. The medication was continued for a month. The aim of the study was to evaluate whether colchicine was able to avoid the post-pericardiotomy syndrome. The post pericardiotomy syndrome occurred in 19.4% of patients in the…
SOLID-TIMI 52: Darapladib to reduce new cardiovascular events after myocardial infarction
This study randomized 1: 1 patient who had been hospitalized for acute coronary syndrome within 30 days after entry to darapladib versus placebo study. A total of 6504 patients were included in the darapladib group and 6522 in the placebo group. At a mean of 2.5 years follow-up a combined cardiovascular events rate was observed,…
ODYSSEYCOMBO II: Alirocumab more effective than ezetimibe when statins are insufficient
The aim of the study was to show a reduction in LDL cholesterol with the use of monoclonal antibody alirocumab as an adjunct therapy to statins in patients already receiving the maximum tolerated dose of statins. This study randomized 720 patients with hypercholesterolemia and high cardiovascular risk to alirocumab 75 mg subcutaneously every 2 weeks…
SIGNIFY: Ivabradine does not reduce events in patients with stable coronary disease
The increase in heart rate in the setting of chronic coronary artery disease is associated with poor prognosis, especially increased risk of acute myocardial infarction. Reducing heart rate with ibravadina inhibitor may confer symptomatic benefit of angina and reduce coronary events in patients with chronic coronary disease and a resting heart rate ≥ 70 bpm.…
- 1
- 2